ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics Inc

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Wednesday, shares of ADMA Biologics Inc (Symbol: ADMA) entered into oversold territory, hitting an RSI reading of 29.8, after changing hands as low as $17.35 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 68.2. A bullish investor could look at ADMA's 29.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ADMA shares:
Looking at the chart above, ADMA's low point in its 52 week range is $10.21 per share, with $25.67 as the 52 week high point — that compares with a last trade of $17.50.
LMAT Dividend History
Institutional Holders of JKHY
Top 10 Hedge Funds Holding CDNS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ADMA Biologics Becomes Oversold

In trading on Tuesday, shares of ADMA Biologics Inc (Symbol: ADMA) crossed below their 200 day moving average of $18.82, changing hands as low as $18.71 per share. ADMA Biologics Inc shares are currently trading off about 7.5% on the day. The chart below shows the one year performance of ADMA shares, versus its 200 day moving average:
Looking at the chart above, ADMA's low point in its 52 week range is $10.21 per share, with $25.67 as the 52 week high point — that compares with a last trade of $18.89.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
Also see:
Institutional Holders of TUTI
ARTC Split History
NCU Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ADMA Makes Notable Cross Below Critical Moving Average

ADMA Biologics ADMA reported lower-than-expected results for the first quarter. Adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate of 16 cents. Revenues of $114.8 million (up 40% year over year) also missed the Zacks Consensus Estimate of $119 million.
Consequently, the stock has plunged post the earnings announcement on May 7.
Nonetheless, the company raised its annual revenue guidance for 2025 and 2026, concurrent with the quarterly results.
A single quarter's results should not determine any investment decision. Let us delve into ADMA’s fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice.
Asceniv’s Performance Fuels ADMA’s Growth
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease.
Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company’s proprietary microneutralization assay.
Demand was record high in the first quarter. Consequently, ADMA expects Asceniv’s total revenue share to expand throughout 2025 and beyond.
ADMA anticipates accelerating new patient starts and further penetration in existing institutions, which would significantly expand its peak revenue potential driven by ramp up of long-term high-titer plasma supply contracts and continued benefit in real-world patient outcomes.
ADMA’s Progress With Another Candidate
ADMA expects to generate initial, proof-of-concept animal data before 2025-end for its lead R&D pipeline program, SG-001, a hyperimmune globulin targeting S. pneumonia.
ADMA believes that SG-001 has the potential to generate $300-500 million or more in high-margin annual revenues, with IP protection through at least 2037.
ADMA Raises Financial Targets
Along with providing first-quarter results, ADMA updated its outlook for 2025 and 2026. ADMA now expects to generate revenues of more than $500 million in 2025 and $625 million in 2026 (previous guidance: more than $490 million in 2025 and $605 million in 2026). Net income is projected to exceed $175 million in 20225 (same as before) and expected to increase to $245 million or more for 2026 (previous guidance: exceed $235 million in 2026).
ADMA’s Share Repurchase Program to Boost Earnings
ADMA recently authorized a common stock repurchase program of up to $500 million. The buyback will boost the bottom line.
ADMA’s Price Performance, Valuation & Estimates
Shares of ADMA have surged 37.7% year to date against the industry’s decline of 7.4%. The stock has outperformed the sector and the S&P 500 in this timeframe.
ADMA Outperforms Industry, Sector And S&P 500 Index
Image Source: Zacks Investment Research
From a valuation perspective, ADMA is expensive at this moment. Going by the price/sales ratio, ADMA’s shares currently trade at 10.46x forward sales, higher than its mean of 3.32x and the industry’s 1.65x.
Image Source: Zacks Investment Research
Estimate Movement
Image Source: Zacks Investment Research
The EPS estimate for 2025 has moved north 1 cent to 71 cents but remained unchanged at 93 cents for 2026.
Invest in ADMA Stock
Large biotech companies are generally considered safe havens for investors interested in this sector. ADMA Biologics, which competes with Takeda TAK and Grifols GRFS in the U.S. market for plasma-derived products, should maintain momentum in the upcoming quarters. Incremental additional penetration of Asceniv should accelerate near-term revenue growth.
While the first-quarter performance was disappointing, the targeted market has significant growth potential. Management expects additional opportunities for ADMA to continue to grow substantially in the underserved, immune-compromised and co-morbid patient population despite the availability of standard-of-care therapy.
Additionally, ADMA conducts all its manufacturing operations, end-market sales, and customer engagements exclusively within the United States. The tariffs implemented on foreign goods, services, and manufacturing are not expected to have an impact on ADMA and its supply chain or production operations.
The recent FDA approval for its innovative yield enhancement production process supports revenue growth and margin expansion opportunities. Hence, any dip can be used as a buying opportunity. For investors already owning the stock, staying invested would be a prudent move.
ADMA currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Grifols, S.A. (GRFS) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?

Viatris Inc. VTRS delivered first-quarter adjusted earnings of 50 cents per share, which beat the Zacks Consensus Estimate of 49 cents. The company recorded adjusted earnings of 67 cents per share in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Total revenues were $3.25 billion, down 11% year over year. The top line included product sales and other revenues. Nonetheless, revenues beat the Zacks Consensus Estimate of $3.23 billion.
Shares are trading up in response to better-than-expected results. VTRS’ share price has dropped 30.1% year to date compared with the industry’s 0.9% decline.
Image Source: Zacks Investment Research
All growth rates mentioned below are on a year-over-year basis.
VTRS’ Q1 Sales in Detail
Sales totaled $3.2 billion, down 11%. Sales were down 3% on a divestiture-adjusted operational basis compared to the prior-year results.
The company reports under four segments — Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ), and Greater China.
Sales from Developed Markets amounted to $1.9 billion, down 3% on a divestiture-adjusted operational basis. The reported figure missed the Zacks Consensus Estimate of $1.93 billion.
Sales from Emerging Markets totaled $519.9 million, down 5% on a divestiture-adjusted operational basis. The figure beat the Zacks Consensus Estimate of $464 million.
JANZ generated sales of $276.1 million, down 6% on a divestiture-adjusted operational basis. Sales missed the Zacks Consensus Estimate of $309 million.
Sales from Greater China totaled $555.5 million, up 4% on a divestiture-adjusted operational basis. The figure beat the Zacks Consensus Estimate of $553 million.
Based on product category, revenues from Brands decreased 8% to $2.1 billion. On a divestiture-adjusted operational basis, sales increased 3%, reflecting the expansion of the portfolio in Emerging Markets and strong growth in Greater China and Developed Markets.
Among Brands, Lipitor sales totaled $388 million, relatively flat year over year. Norvasc sales decreased to $172.3 million from $176.3 million a year ago. Lyrica sales declined to $112.6 million from $114.2 million.
Yupelri sales totaled $58.3 million, up from $55.2 million in the year-ago quarter.
Generics, which includes diversified product forms such as extended-release oral solids, injectables, transdermals, topicals and complex generics, posted revenues of $1.1 billion, down 16%. On an operational change basis, sales were down 11%.
The decline in generics’ sales reflects the expected negative impact from the Indore facility, partially offset by growth in certain complex products in North America, strong performance across key European markets and volume growth in JANZ.
Following an inspection of Viatris' oral finished dose manufacturing facility in Indore, India, in June 2024, the company received a warning letter and import alert from the FDA in December 2024.
The import alert affects 11 actively distributed products, including lenalidomide and everolimus.
Viatris generated $67 million in new generic product revenues. It expects to generate $450-$550 million in new product revenues in 2025.
Adjusted gross margin was 55.9%, down from 58.8% reported in the year-ago quarter.
So far this year, VTRS has returned more than $450 million of capital to its shareholders, including over $300 million in share repurchases and $143 million in dividends paid.
VTRS expects $500 million to $650 million in total share repurchases in 2025.
VTRS Updates 2025 Guidance
Total revenues are still projected to be in the band of $13.5-$14 billion. Adjusted earnings per share are now expected to be in the range of $2.16-$2.30 (previous guidance: $2.12-$2.26). The guidance for the bottom line was updated to reflect the impact of acquired IPR&D and share repurchases.
Viatris Inc. Price, Consensus and EPS Surprise
Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote
Other Updates
Results from the phase III open-label, long-term extension study for Effexor required for approval in Japan were positive. VTRS filed applications to the Ministry of Health, Labor and Welfare for approval of Effexor SR Capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor to treat adults with generalized anxiety disorder.
VTRS announced positive top-line results from two pivotal phase III studies of its novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. All primary and secondary endpoints were met in both the phase III studies. MR-107A-02 demonstrated statistically significant and clinically meaningful results.
VTRS is targeting to submit a new drug application to the FDA by the end of 2025.
Our Take on VTRS’ Q1 Performance
VTRS’ performance in the first quarter was encouraging, with both the top and the bottom lines comfortably beating their respective estimates. Sales from branded drugs benefit from the company’s portfolio expansion in Emerging Markets, along with robust growth in Greater China and Developed Markets.
VTRS’ Zacks Rank and Stocks to Consider
Viatris currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma/biotech sector are Bayer BAYRY, ADMA Biologics Inc. ADMA and Beam Therapeutics Inc. BEAM, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Bayer’s earnings per share have increased from $1.17 to $1.23 for 2025. During the same time, earnings per share have increased from $1.27 to $1.31 for 2026. Year to date, shares of BAYRY have rallied 35.1%.
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 70 cents to 71 cents for 2025. During the same time, earnings per share estimates for 2026 are unchanged at 93 cents. Year to date, shares of ADMA have gained 12%.
ADMA’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 14.68%.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.45 to $4.30 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.94 to $4.65.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
Beam Therapeutics Inc. (BEAM) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Viatris Inc. (VTRS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains

Krystal Biotech KRYS reported first-quarter 2025 earnings per share (EPS) of $1.20, which missed the Zacks Consensus Estimate of $1.38. Nonetheless, the reported EPS was up from 3 cents posted in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Revenues of $88.1 million surged 95% year over year but missed the Zacks Consensus Estimate of $95 million. Revenues came in solely from the sales of Vyjuvek.
Shares of the company are trading down in response to the disappointing results.
Shares of KRYS have risen 3.6% year to date against the industry’s 2.2% decline.
Image Source: Zacks Investment Research
KRYS’ Q1 Results in Detail
In 2023, the FDA approved Vyjuvek, the first-ever revocable gene therapy for treating patients aged six months or older with dystrophic epidermolysis bullosa (DEB). DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1.
As of April, Krystal secured more than 540 reimbursement approvals for Vyjuvek in the United States. It also achieved positive access determinations for 97% of lives covered under commercial and Medicaid plans.
The gross margin in the reported quarter was 94%.
Research and development expenses amounted to $14.2 million, up 30.1% year over year. Selling, general and administrative expenses totaled $32.7 million, up 25.6% from the year-ago level.
Cash, cash equivalents, and investments totaled $765.3 million as of March 31, 2025.
Krystal Biotech, Inc. Price, Consensus and EPS Surprise
Krystal Biotech, Inc. price-consensus-eps-surprise-chart | Krystal Biotech, Inc. Quote
KRYS Makes Good Pipeline Progress
Last month, the European Commission approved Vyjuvek for the treatment of wounds in patients with DEB who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. KRYS is on track to launch the drug in Germany in mid-2025.
Krystal Biotech has also filed a new drug application with Japan’s Pharmaceuticals and Medical Devices Agency. A decision on the same is expected in the second half of 2025.
KRYS is also advancing a robust preclinical and clinical pipeline of investigational genetic medicines in the fields of respiratory, oncology, dermatology, ophthalmology and aesthetics.
Krystal Biotech is evaluating KB407 for the treatment of cystic fibrosis. Enrollment is ongoing in cohort 3 of CORAL-1, a multi-center, dose escalation study evaluating KB407 in patients with CF, regardless of their underlying genotype.
KRYS received full sanctioning of the study protocol by the Cystic Fibrosis Foundation Therapeutic Development Network in January and remains on track for an interim molecular data readout for cohort 3 patients in mid-2025.
Another candidate, KB408, is being evaluated for the treatment of alpha-1 antitrypsin deficiency. Enrollment is ongoing in cohort 2 and is working to enroll in Cohort 3 of SERPENTINE-1, an open-label, single-dose escalation study in adult patients with AATD.
Vyjuvek is referred to as B-VEC outside the country. The company is also evaluating KB803 (B-VEC formulated as an eyedrop) for ocular complications of DEB. Enroll is ongoing in its ongoing natural history study to prospectively collect data on the frequency of corneal abrasions in patients with DEB.
This will allow KRYS to screen eligible patients for its registrational phase III IOLITE study, which will evaluate the effect of KB803 on ocular complications of DEB. Krystal Biotech expects to dose the first patient in the registrational phase III IOLITE study on KB803 later this month.
In April, the FDA cleared the company’s investigational new drug application to evaluate KB801. This is the company’s second clinical-stage ophthalmology program for the treatment of neurotrophic keratitis (NK).
KRYS expects to dose the first patient in EMERALD-1, a randomized, double-blind, placebo-controlled, multi-center Phase 1/2 study evaluating KB801 in moderate-to-severe NK patients, later this month.
Enrollment is ongoing in KYANITE-1, a phase I/II open-label, multi-center, dose escalation and expansion study evaluating inhaled KB707, as monotherapy or in combination, in patients with locally advanced or metastatic solid tumors of the lung.
KRYS’ wholly-owned subsidiary, Jeune Aesthetics, is currently developing a décolleté-specific photo numeric scale for advanced clinical development of KB301. This subsidiary expects to align with the FDA on the scale and enroll the first subject in a multi-center, randomized, placebo-controlled phase II study evaluating KB301 for the treatment of dynamic wrinkles of the décolleté in the fourth quarter.
In February, Jeune Aesthetics completed enrolment in PEARL-2, an ongoing, randomized and placebo-controlled phase I study evaluating KB304 for the treatment of wrinkles. Top-line results from the study are expected in the second half.
KRYS also expects to initiate the phase II portion of its phase I/II JADE-1 trial evaluating KB105 for the treatment of TGM1-deficient lamellar ichthyosis in pediatric patients in 2026.
KRYS’ Zacks Rank and Stocks to Consider
Krystal carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the pharma/biotech sector are Bayer BAYRY, ADMA Biologics Inc. ADMA and Beam Therapeutics Inc. BEAM, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Bayer’s earnings per share have increased from $1.14 to $1.22 for 2025. During the same time, earnings per share have increased from $1.23 to $1.31 for 2026. Year to date, shares of BAYRY have rallied 40.3%.
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 69 cents to 71 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 36.6%.
ADMA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.45 to $4.27 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.94 to $4.80.
BEAM’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.92%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
Beam Therapeutics Inc. (BEAM) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Krystal Biotech, Inc. (KRYS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.06 per share for the first quarter of 2025, missing the Zacks Consensus Estimate of $4.22. Earnings declined 14.7% on a year-over-year basis.
The company reported total revenues of $2.77 billion for the first quarter, which missed the Zacks Consensus Estimate of $2.82 billion. Total revenues rose 3% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe). (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
VRTX’s total revenues comprised cystic fibrosis (“CF”) and other products revenues, as well as other collaboration revenues.
Shares of Vertex have rallied 24.3% so far this year against the industry’s decrease of 2.2%.
Image Source: Zacks Investment Research
VRTX's Q1 Results in Detail
Total revenues rose 9% year over year in the United States to $1.66 billion, while sales outside the United States decreased 5% to $1.11 billion. On the first-quarter conference call, management stated that revenues in ex-U.S. markets were negatively impacted by the availability of an illegal copy product in Russia, where Vertex is experiencing a violation of its intellectual property rights.
The company recorded $10 million of collaboration revenues in the first quarter.
The company’s total product revenues comprise sales of Trikafta/Kaftrio, the newly approved CFTR modulator therapy, Alyftrek (vanza triple) and other product revenues.
Trikafta generated sales worth $2.54 billion, up 2.4% year over year. The product’s sales narrowly missed the Zacks Consensus Estimate of $2.55 billion as well as our model estimate of $2.62 billion.
Alyftrek generated sales worth $53.9 million in the first quarter. Alyftrek, a next-in-class triple combination regimen, was approved by the FDA in December 2024 for treating people with CF aged six years and older. Management is already seeing a steady uptake from all patient groups who are eligible for treatment with Alyftrek.
Revenue from other products decreased 17.4% year over year to $170.8 million.
Other product revenues included $14.2 million in sales of Casgevy, an insignificant amount from the newly approved pain drug, Journavx (suzetrigine) as well as sales of VRTX’s other CF products – Symdeko/Symkevi (marketed as Symkevi in Europe), Orkambi and Kalydeco.
Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy, Casgevy, was approved for two blood disorders, sickle cell disease and transfusion-dependent beta-thalassemia, in multiple regions in late 2023/early 2024.
Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement with support from CRISPR Therapeutics.
Casgevy sales surged 77.5% on a sequential basis, reflecting strong adoption already.
The FDA approved Vertex’s oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, Journavx, for the treatment of adults with moderate-to-severe acute pain in January 2025.
VRTX's Q1 Cost Discussion
Adjusted research and development (R&D) expenses were up 31.2% year over year to $879 million while adjusted selling, general and administrative (SG&A) expenses increased 22.4% to $333 million in the reported quarter due to higher investment in various ongoing clinical studies and higher expenses to support the commercial launch of Journavx.
During the first quarter, Vertex recorded acquired in-process research and development (AIPR&D) costs of $19.8 million compared with $76.8 million reported in the year-ago quarter.
Adjusted operating income was almost $1.18 billion in the quarter, indicating a decrease of almost 12% year over year.
VRTX's 2025 Guidance
The company raised the lower end of its total revenue guidance for full-year 2025.
Vertex now expects total revenues in the range of $11.85-$12 billion for 2025 compared with the previous expectation of $11.75-$12 billion. The Zacks Consensus Estimate for total revenues is pegged at $11.86 billion for 2025.
The updated guidance reflects the continued growth in CF medicines, including the launch of Alyftrek, the uptake of Casgevy and early contributions from the launch of Journavx.
Combined adjusted R&D, AIPR&D and SG&A expense for 2025 is expected in the band of $4.9-$5 billion. The adjusted tax rate is expected to be in the range of 20.5%-21.5%. Both estimates remain unchanged from the previous expectations.
VRTX's Pipeline Update
Besides acute pain, suzetrigine is also being developed in late-stage studies for the treatment of diabetic peripheral neuropathy and painful lumbosacral radiculopathy.
Vertex has a rapidly advancing mid to late-stage pipeline in other disease areas, like APOL1-mediated kidney diseases, alpha-1 antitrypsin deficiency and cell therapy for type I diabetes (T1D).
A phase II study is evaluating VRTX’s oral formulation of next-gen Nav1.8 inhibitor, VX-993, for the treatment of moderate-to-severe acute pain following bunionectomy surgery. Data from the same is expected in the second half of 2025.
VX-993 is also in phase I development for the intravenous formulation.
The acquisition of Alpine in May 2024 added povetacicept to Vertex’s pipeline. Povetacicept is designed to target two proteins, namely BAFF and APRIL, which are jointly responsible for the cause of multiple serious autoimmune diseases.
The phase III RAINIER study is investigating povetacicept for the treatment of IgA nephropathy. Povetacicept is also being evaluated in two phase II basket studies, one in renal diseases and a second in B cell-mediated diseases. Data from these studies is expected later this year.
Vertex is developing zimislecel in the phase III portion of the ongoing phase I/II/III study for treating patients with T1D with severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia. Enrollment and dosing in this study are expected to be completed later in the second quarter of 2025. Vertex plans to submit regulatory filings seeking approval for zimislecel in T1D in 2026.
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
Vertex Pharmaceuticals Incorporated price-consensus-eps-surprise-chart | Vertex Pharmaceuticals Incorporated Quote
VRTX’s Zacks Rank & Stocks to Consider
Vertex currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ADMA Biologics Inc. ADMA and Immunocore Holdings PLC IMCR, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 69 cents to 71 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 38.3%.
ADMA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%.
In the past 60 days, estimates for Immunocore’s loss per share have narrowed from $1.63 to $1.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.83 to $1.68. Year to date, shares of IMCR have gained 3.9%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 31.91%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1.80 per share in the year-ago quarter.
Revenues in the first quarter totaled $14.1 million, up from $7.9 million reported in the year-ago period. Revenues slightly missed the Zacks Consensus Estimate of $14.2 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
SAGE markets its new depression drug Zurzuvae (zuranolone) in partnership with drug giant Biogen BIIB. Zurzuvae, the first and only oral treatment indicated for adults with postpartum depression (PPD), was approved in August 2023 and was commercially launched in December 2023.
Year to date, shares of Sage Therapeutics have rallied 40% against the industry’s decline of 4%.
Image Source: Zacks Investment Research
More on SAGE's Q1 Earnings
Total revenues in the reported quarter comprised collaboration revenues – related party and other collaboration revenues.
Collaboration revenues from the sale of Zurzuvae were $13.8 million in the first quarter, increasing 21% on a sequential basis.
Sage Therapeutics and partner Biogen equally share profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan, Taiwan and South Korea, where Shionogi holds the rights) and pays royalties to SAGE.
Per Sage Therapeutics, more than 3,000 prescriptions were shipped and delivered during the quarter, representing an increase of 22% sequentially.
Research & development (R&D) expenses were $22.8 million, down 68.2% from the year-ago quarter’s levels. The downside was due to recent restructuring measures, including reduced headcount and lower spending on early-stage pipeline programs and discontinuation of ongoing clinical studies.
Selling, general and administrative expenses (SG&A) increased 9.5% from the prior-year quarter’s figure to $57.6 million. The upside was due to higher commercialization cost and legal expenses associated with the strategic alternatives review process.
The company had $424 million in cash, cash equivalents and marketable securities as of March 31, 2025 compared with $504 million as of Dec. 31, 2024. This cash balance, combined with expected funding from collaboration revenues and potential savings from the recent reorganization, is expected to support SAGE’s ongoing operations into mid-2027.
2025 Guidance
The company anticipates operating expenses to substantially decline in 2025 compared with 2024. SAGE also expects the Zurzuvae joint commercialization investment to increase in 2025.
SAGE's Key Pipeline Updates
SAGE is currently evaluating SAGE-324 for potential indications, including seizures in developmental and epileptic encephalopathies (DEEs). An update on the next steps of development of SAGE-324, if any, is expected in mid-2025.
We remind investors that in September 2024, Biogen terminated its rights under the collaboration and license agreement with SAGE related to the development of neurology candidate, SAGE-324, for treating essential tremor (ET). A phase II study on SAGE-324 for the chronic treatment of ET failed in July 2024.
Sage Therapeutics is developing SAGE-319, its wholly-owned extra-synaptic-preferring GABA-A receptor-positive allosteric modulator, as a potential treatment for behavioral symptoms associated with certain neurodevelopmental disorders. Data from a phase I multiple ascending dose study on SAGE-319 is expected by late 2025.
The company is exploring various strategic alternatives to maximize shareholders’ value.
Sage Therapeutics, Inc. Price, Consensus and EPS Surprise
Sage Therapeutics, Inc. price-consensus-eps-surprise-chart | Sage Therapeutics, Inc. Quote
SAGE's Zacks Rank & Stocks to Consider
Sage Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ADMA Biologics Inc. ADMA and Beam Therapeutics Inc. BEAM, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 69 cents to 71 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 40.6%.
ADMA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.43 to $4.27 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.94 to $4.80. Year to date, shares of BEAM have lost 20.6%.
BEAM’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.92%.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Biogen Inc. (BIIB) : Free Stock Analysis Report
Beam Therapeutics Inc. (BEAM) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in ADMA Biologics Inc (Symbol: ADMA), where a total volume of 18,263 contracts has been traded thus far today, a contract volume which is representative of approximately 1.8 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 50.6% of ADMA's average daily trading volume over the past month, of 3.6 million shares. Especially high volume was seen for the $30 strike call option expiring January 16, 2026, with 3,116 contracts trading so far today, representing approximately 311,600 underlying shares of ADMA. Below is a chart showing ADMA's trailing twelve month trading history, with the $30 strike highlighted in orange:
Marriott International, Inc. (Symbol: MAR) options are showing a volume of 12,159 contracts thus far today. That number of contracts represents approximately 1.2 million underlying shares, working out to a sizeable 50.1% of MAR's average daily trading volume over the past month, of 2.4 million shares. Especially high volume was seen for the $210 strike put option expiring May 16, 2025, with 3,924 contracts trading so far today, representing approximately 392,400 underlying shares of MAR. Below is a chart showing MAR's trailing twelve month trading history, with the $210 strike highlighted in orange:
And Humana Inc. (Symbol: HUM) options are showing a volume of 8,821 contracts thus far today. That number of contracts represents approximately 882,100 underlying shares, working out to a sizeable 49.3% of HUM's average daily trading volume over the past month, of 1.8 million shares. Especially high volume was seen for the $310 strike call option expiring May 16, 2025, with 3,074 contracts trading so far today, representing approximately 307,400 underlying shares of HUM. Below is a chart showing HUM's trailing twelve month trading history, with the $310 strike highlighted in orange:
For the various different available expirations for ADMA options, MAR options, or HUM options, visit StockOptionsChannel.com.
Also see:
Analyst Actions
MRLB Options Chain
DVMT Insider Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy Monday Option Activity: ADMA, MAR, HUM

(RTTNews) - ADMA Biologics, Inc. (ADMA) Monday said that the United States Food and Drug Administration (FDA) has approved the company's innovative production yield enhancement process.
The company noted that the innovative process has shown an ability to increase production yields by about 20% from the same starting plasma volume.
"This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond," said Adam Grossman, President and Chief Executive Officer of ADMA.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

FDA Approves ADMA Biologics' Innovative Production Yield Enhancement Process

Bristol-Myers Squibb Company BMY reported first-quarter 2025 adjusted earnings per share (EPS) of $1.80, which comfortably beat the Zacks Consensus Estimate of $1.51. In the year-ago quarter, BMY posted an adjusted loss per share of $4.40. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Total revenues of $11.2 billion surpassed the Zacks Consensus Estimate of $10.7 billion. However, revenues were down 6% from the year-ago period’s level due to a decline in Legacy portfolio sales.
BMY’s shares have lost 12.3% year to date compared with the industry's decline of 5.3%.
Image Source: Zacks Investment Research
Revenues decreased 7% to $7.9 in the United States. International revenues decreased 2% year over year to $3.3 billion.
Growth Portfolio Fuels BMY’s Q1 Top Line
BMY’s Growth Portfolio comprises drugs like Opdivo, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Abecma, Sotyku, Krazati and Cobenfy.
Revenues from the Growth portfolio totaled $5.6 billion, up 16% from the year-ago level. Sales grew 18% when adjusted for foreign exchange impacts.
Growth Portfolio revenues were primarily driven by higher demand for Opdivo, Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag.
Total sales of the immuno-oncology drug Opdivo, approved for multiple cancer indications, increased 9% year over year to $2.26 billion. The figure beat the Zacks Consensus Estimate of $2.17 billion and our model estimate of $2.14 billion.
However, sales of the rheumatoid arthritis drug Orencia decreased 4% to $770 million.
Melanoma drug Yervoy contributed $624 million to the top line. The figure rose 7% year over year. Yervoy sales beat both the Zacks Consensus Estimate and our model estimate of $597 million.
Reblozyl sales surged 35% year over year to $478 million. Reblozyl sales were in line with the Zacks Consensus Estimate but missed our model estimate of $493.9 million.
Opdualag sales jumped 23% to $252 million. Opdualag sales missed the Zacks Consensus Estimate of $262 million and our model estimate of $257 million.
Breyanzi sales skyrocketed 146% to $263 million and beat the Zacks Consensus Estimate of $240 million and our model estimate of $260 million. Camzyos sales, too, surged 89% to $159 million.
Sales of Zeposia declined 3% to $107 million. Abecma sales increased 26% to $103 million.
Sotyktu sales totaled $55 million. Krazati raked in sales of $48 million. The newly approved schizophrenia drug, Cobenfy, generated sales of $27 million.
Decline in Legacy Portfolio Revenues Pulls Down BMY in Q1
Revenues for the Legacy Portfolio plunged 20% to $5.64 billion due to the continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the effects of the U.S. Medicare Part D redesign.
Eliquis sales of $3.56 billion were down 4%. Nonetheless, sales beat both the Zacks Consensus Estimate of $3.3 billion and our model estimate of $3.4 billion.
Please note that Bristol-Myers has a collaboration agreement with Pfizer PFE for Eliquis. The companies collaborated in 2007. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMY a sales-based fee.
Multiple myeloma (MM) drug Revlimid revenues plummeted 44% to $936 million due to lower demand on account of generic erosion. Sales surpassed both the Zacks Consensus Estimate of $885 million and our model estimate of $764.3 million.
MM drug Pomalyst generated sales of $658 million, down 24% year over year.
Leukemia drug Sprycel sales nosedived 53% year over year to $175 million due to generic competition.
Abraxane revenues declined 52% to $105 million.
Costs and Margin
Gross margin decreased to 73.1% from 75.5% in the year-ago quarter due to product mix. Adjusted research and development expenses decreased 5% to $2.2 billion. Adjusted marketing, selling and administrative expenses decreased 20% to $1.6 billion due to BMY’s cost-cutting initiative.
BMY’s Key Pipeline Updates
The FDA updated the prescribing information for Camzyos, simplifying treatment options for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and expanding patient eligibility by reducing contraindications.
Earlier, the late-stage ODYSSEY-HCM study evaluating Camzyos for the treatment of adult patients with symptomatic New York Heart Association class II-III non-obstructive hypertrophic cardiomyopathy did not meet its dual primary endpoints.
The late-stage study evaluating Cobenfy as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia did not meet the threshold for statistical significance for the primary endpoint.
The FDA approved Opdivo plus Yervoy as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma.
Bristol Myers Squibb Company Price, Consensus and EPS Surprise
Bristol Myers Squibb Company price-consensus-eps-surprise-chart | Bristol Myers Squibb Company Quote
BMY Raises 2025 Guidance
Bristol-Myers raised its annual revenue guidance to $45.8-$46.8 billion from $45.5 billion on the back of strong performance of the Growth Portfolio, better-than-expected Legacy Portfolio sales in the first quarter of 2025 and a favorable impact of approximately $500 million related to foreign exchange rates.
The Zacks Consensus Estimate for 2025 revenues is pinned at $45.82 billion.
The company now expects adjusted earnings to be in the range of $6.70-$7 (previous guidance: $6.55-$6.85). The Zacks Consensus Estimate for 2025 EPS is pegged at $6.76.
Management added that the stated guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China but do not account for potential pharmaceutical sector tariffs.
Our Take on BMY’s Q1 Performance
BMY’s better-than-expected quarterly results were driven by higher demand for Opdivo, Breyanzi, Reblozyl and Camzyos.
As expected, sales in the Legacy portfolio declined, but the deterioration was lower than expected.
Consequently, the guidance was raised to reflect this performance.
The strategic productivity initiative undertaken by the company is boosting the bottom line.
While the performance definitely boosts investor sentiment, BMY has a few challenges to navigate.
BMY’s Zacks Rank & Stocks to Consider
Bristol-Myers currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the biotech sector are ANIP Pharmaceuticals ANIP and ADMA Biologics ADMA. While ANIP currently sports a Zacks Rank #1 (Strong Buy), ADMA carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $5.54 to $6.36. EPS estimates for 2026 have increased from $6.75 to $7.14 during the same period.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 17.32%.
In the past 30 days, estimates for ADMA Biologics’ 2025 EPS have increased from 69 cents to 71 cents. The estimate for 2026 earnings per share has remained constant at 93 cents. Year to date, shares of ADMA Biologics have gained 29%.
ADMA’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 32.8%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.